Gufic Biosciences Limited (NSE:GUFICBIO)

Market Cap	38.53B
Revenue (ttm)	8.20B
Net Income (ttm)	696.50M
Shares Out	n/a
EPS (ttm)	6.95
PE Ratio	55.32
Forward PE	n/a
Dividend	0.10 (0.02%)
Ex-Dividend Date	Sep 17, 2024

Volume	59,308
Average Volume	73,878
Open	399.40
Previous Close	397.10
Day's Range	382.50 - 400.00
52-Week Range	298.80 - 504.25
Beta	0.28
RSI	55.56
Earnings Date	May 29, 2025

About CTI BioPharma

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 1,491
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUFICBIO

Financial Performance

In 2024, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.